NCT06852352Toboroz
An Exploratory Study to Confirm Efficacy of Modified Deep Cervical Lymphovenous Anastomosis (LVA) in Alzheimer's Disease/ Parkinson's Disease
A Prospective, Single-center, Single-arm, Exploratory, 24-Month Study to Confirm Efficacy of Modified Deep Cervical Lymphovenous Anastomosis (LVA) in Subjects With Alzheimer's Disease/ Parkinson's Disease
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2025. márc. 11. · Több mint 12 hónapja nem frissült - kérdezd meg a helyszínt, nyitott-e még
Rövid összefoglaló (regiszter, angolul)
Alzheimer's disease (AD) and Parkinson's disease (PD) are characterized by pathological protein accumulation in the brain-Aβ/tau in AD and α-synuclein in PD. Recent studies have indicated that age-related lymphatic vessel atrophy compromises the metabolic clearance capacity of meningeal lymphatic vessels, potentially disrupting the equilibrium between production and clearance of Aβ/α-synuclein, ultimately leading to pathological accumulation of these proteins within the brain. Deep cervical lymphovenous anastomosis (LVA), a surgical technique proven effective in restoring lymphatic drainage in lymphedema, may enhance clearance of neurotoxic proteins by improving cervical lymphatic outflow. This project aims to evaluate the efficacy of modified deep cervical LVA in treating AD and PD, establishing a novel therapeutic strategy to modify disease progression and improve quality of life in neurodegenerative disorders, additionally offering the pathogenic mechanisms underlying neurodegenerative disorders.
- Állapot (regiszter)
- Toboroz
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 160 (tervezett)
- Első benyújtás
- 2025. febr. 18.
- Kezdés
- 2025. febr. 28.
- Elsődleges befejezés
- 2027. jún. 30.
- Fő szponzor
- Zhejiang Provincial People's Hospital
- Betegségek
- Alzheimer-kór, Parkinson-kór
- NCT-szám
- NCT06852352
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó
- Tervezett résztvevők: 160
- 2025. febr. 28. és az elsődleges befejezés (2027. jún. 30.) között
- 1 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Más betegség
- MRI results suggesting intracranial active/acute pathologies, including infections, space-occupying lesions, major hemorrhages, or ≥4 lobar microhemorrhages;
- Conditions predisposing to increased intracranial hemorrhage risk, such as hematological disorders, hemorrhagic/coagulation disorders;
- Severe cardiac disease or hemodynamic instability;
- Uncontrolled severe hypertension;
- Substance use disorders (including illicit drugs, anesthetics, and alcohol dependence);
- Active severe infections, including HIV positivity and acute critical infections;
- Severe psychiatric disorders or significant suicide risk;
- History of untreated/uncured malignancies;
Laborértékek
- Functional impairment of vital organs (cardiac, pulmonary, renal, hepatic), including reduced left ventricular ejection fraction, prolonged QT interval, severe pulmonary diseases, and severe hepatic/renal insufficiency
Egyéb
- Contraindications for MRI, ICG angiography, or PET scanning
- Contraindications for lumbar puncture
- Poorly controlled thyroid dysfunction;
- Cerebrovascular or systemic vasculopathy;
- Chronic hypnotic use (more than twice weekly for over one month);
- Participation in other interventional clinical trials within preceding 3 months;
- Poor compliance with inability/unwillingness to complete scheduled postoperative follow-ups;
- Other investigator-determined contraindications for trial participation.
Kiket keres a vizsgálat
- Alzheimer's disease:
- Male or female, the age ranged from 50 to 75 years old
- Informed consent signed and dated by patient or legal representative
- Patients diagnosed principally with mild cognitive impairment or dementia caused by Alzheimer's disease
- Positive result of Amyloid PET imaging (Centiloids ≥37)
- HAMD score ≤17
- Hachinski score ≤4 Patients who meet ASA (American Society of Anesthesiologists) grade I-III criteria
- Parkinson's disease:
- Male or female, the age ranged from 50 to 80 years old
- Informed consent signed and dated by patient or legal representative
- Patients diagnosed with Parkinson's disease or probable Parkinson's disease according to the Clinical Diagnostic Criteria for Parkinson's Disease in China (2016) or MDS
- Stage I-IV patients according to Hoehn and Yahr Scale
- Patients documented history of Parkinson's disease for more than 2-5 years to ensure clinical stability of symptoms and exclude the possibility of early misdiagnosis of other conditions
Életkor a regiszterben: 50 év – 80 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (1)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Zhejiang Provincial People's Hospital | Hangzhou | Kína | Toboroz |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.